Study Shows Combining Chemotherapy With Targeted Drug Boosts Response in Chronic Lymphocytic Leukemia
December 10, 2017
December 10, 2017
BOSTON, Massachusetts, Dec. 10 -- The Dana-Farber Cancer Institute issued the following news release:
Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.
"We're combining the most potent chemotherapy re . . .
Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.
"We're combining the most potent chemotherapy re . . .